Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine (90 views)
Viruses (ISSN: 1999-4915linking, 1999-4915electronic), 2022 Mar 28; 14(4): N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Review,
Impact factor: 5.048, 5-year impact factor: 3.64
Url: Not available.
Keywords: Antiviral Agents Therapeutic Use, Carcinoma, Hepatocellular Drug Therapy, Hepatitis B Surface Antigens, Hepatitis B Virus Genetics, Chronic Drug Therapy, Humans, Liver Neoplasms Drug Therapy, Precision Medicine, Hbv Functional Cure, Interferon-α, Antiviral Treatment, Chronic Hepatitis B, Nucleos(t)ide Analogues,
Affiliations:
*** IBB - CNR ***
Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Department of Medical Specialties, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy.
Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy.
Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56127 Pisa, Italy.
References:
Not available.
Viruses (ISSN: 1999-4915linking, 1999-4915electronic), 2022 Mar 28; 14(4): N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Review,
Impact factor: 5.048, 5-year impact factor: 3.64
Url: Not available.
Keywords: Antiviral Agents Therapeutic Use, Carcinoma, Hepatocellular Drug Therapy, Hepatitis B Surface Antigens, Hepatitis B Virus Genetics, Chronic Drug Therapy, Humans, Liver Neoplasms Drug Therapy, Precision Medicine, Hbv Functional Cure, Interferon-α, Antiviral Treatment, Chronic Hepatitis B, Nucleos(t)ide Analogues,
Affiliations:
*** IBB - CNR ***
Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Department of Medical Specialties, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy.
Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy.
Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56127 Pisa, Italy.
References:
Not available.
Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
The currently available antiviral treatments (Peg-Interferon-α and Nucleos(t)ide Analogues, NA) for chronic hepatitis B (CHB) achieve a functional cure (serum HBsAg and HDV-DNA clearance) of HBV infection in a limited number of patients. Nevertheless, the continuous pharmacological suppression of viral replication by NA halts liver disease progression lowering the risk of HCC development and improving the survival. In the near future, to fully exploit the potential of old and new drugs for HBV treatment a personalized approach to the patients will be required according to an accurate definition of their virologic, immunologic and clinical profile.
The currently available antiviral treatments (Peg-Interferon-α and Nucleos(t)ide Analogues, NA) for chronic hepatitis B (CHB) achieve a functional cure (serum HBsAg and HDV-DNA clearance) of HBV infection in a limited number of patients. Nevertheless, the continuous pharmacological suppression of viral replication by NA halts liver disease progression lowering the risk of HCC development and improving the survival. In the near future, to fully exploit the potential of old and new drugs for HBV treatment a personalized approach to the patients will be required according to an accurate definition of their virologic, immunologic and clinical profile.
Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
No results. |
Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
Other filter: ([btitle,keywords] "Antiviral Agents The ...
Ciancio A, Ribaldone DG, Dotta A, Giordanino C, Sacco M, Fagoonee S, Pellicano R, Saracco GM
* Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents (120 views)
Liver Int (ISSN: 1478-3223linking), 2021 Feb; 41(2): 276-287.
Impact Factor: 5.175
View Export to BibTeX Export to EndNote
Costanzo M, De Giglio MAR, Roviello GN
* SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus (558 views)
Curr Med Chem (ISSN: 0929-8673linking, 1875-533xelectronic), 2020 Apr 16; 27(27): 4536-4541.
Impact Factor: 4.184
View Export to BibTeX Export to EndNote
De Falco S, Ruvo M, Verdoliva A, Scarallo A, Raimondo D, Raucci A, Fassina G
* N-terminal myristylation of HBV preS1 domain enhances receptor recognition (1247 views)
J Pept Res (ISSN: 1397-002x, 1397-002xlinking), 2001 May; 57(5): 390-400.
Impact Factor: 1.522
View Export to BibTeX Export to EndNote
* Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents (120 views)
Liver Int (ISSN: 1478-3223linking), 2021 Feb; 41(2): 276-287.
Impact Factor: 5.175
View Export to BibTeX Export to EndNote
Costanzo M, De Giglio MAR, Roviello GN
* SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus (558 views)
Curr Med Chem (ISSN: 0929-8673linking, 1875-533xelectronic), 2020 Apr 16; 27(27): 4536-4541.
Impact Factor: 4.184
View Export to BibTeX Export to EndNote
De Falco S, Ruvo M, Verdoliva A, Scarallo A, Raimondo D, Raucci A, Fassina G
* N-terminal myristylation of HBV preS1 domain enhances receptor recognition (1247 views)
J Pept Res (ISSN: 1397-002x, 1397-002xlinking), 2001 May; 57(5): 390-400.
Impact Factor: 1.522
View Export to BibTeX Export to EndNote
3 Records (3 excluding Abstracts).
Total impact factor: 10.881 (10.881 excluding Abstracts).
Total 5 year impact factor: 6.234 (6.234 excluding Abstracts).
Total impact factor: 10.881 (10.881 excluding Abstracts).
Total 5 year impact factor: 6.234 (6.234 excluding Abstracts).
90 views. Last view on Sunday 13 October 2024, 2:49:59
ibb.cnr.it
